Cure8 research brief
This meta-analysis pulls together early trial evidence that TL1A antagonists may improve clinical, endoscopic, and histologic outcomes in both UC and CD and reports an overall acceptable short-term safety profile—information relevant to patients and clinicians tracking new treatment options.
Patients with ulcerative colitis or Crohn's disease, clinicians treating IBD, and researchers in IBD drug development
This paper is a systematic review and meta-analysis (abstract-level) summarizing 12 studies of TL1A antagonists in adult IBD through October 2025. The authors report pooled clinical response rates, odds ratios for clinical remission, endoscopic outcomes (improvement and remission), and histologic–endoscopic mucosal improvement (HEMI).
Short-term safety data show common mild adverse events (noted as infections/infestations) and low rates of serious adverse events (~3–5%). The abstract indicates promise for anti‑TL1A as an emerging therapeutic option but does not provide detailed trial-level methods, patient populations, or long-term safety data in this abstract.
Decisions about treatment should rely on full trial reports and clinician discussion.
Abstract-level synthesis; does not provide full trial methods, heterogeneity, or long-term safety data. TL1A antagonists are an investigational/ emerging class and not yet standard of care.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Competing interests: MKP, VS, KB, CLB, KG, AY, SC, MS and MKR declare no competing interest. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Clinical trial number: Not applicable. Disclaimer: The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology or the printer/publishers are responsible for the results/findings and content of this article.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This narrative review surveys novel biomarkers and therapeutic strategies for adult IBD, topics that could affect diagnosis, monitoring, and future treatment options for people with Crohn's disease or ulcerative colitis.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Arthritis is a common and meaningful extraintestinal problem for people with IBD; understanding diagnosis and treatment options can help patients and clinicians seek appropriate multidisciplinary care.
